Dhanusha Sabanathan Clinical Oncology Society of Australia Annual Scientific Meeting 2022

Abstracts this author is presenting:

• Phase 3, randomized, double-blind, placebo-controlled study of Pembrolizumab+Chemotherapy in patients with HR+/HER2− locally recurrent inoperable or metastatic breast cancer (mBC): KEYNOTE-B49 — Poster session 1